HeartBeam receives two new patents on its core VECG technology from USPTO

HeartBeam announced that it has received two new patents on its core vector electrocardiography VECG technology from the United States Patent and Trademark Office. HeartBeam now has 14 issued and allowed US patents and 4 international patents for its VECG technology which collects 3D signals of the heart and converts them into a 12-lead ECG. “HeartBeam’s core VECG technology is designed to be used with portable, patient-friendly devices such as a credit-card sized system, an extended wear patch, or watch to enable physicians to monitor patients and identify cardiac health trends outside of a medical facility,” said Branislav Vajdic, PhD, CEO and Founder of HeartBeam. “These new patents reinforce our strategic vision which is founded on developing and protecting our novel VECG technology and product pipeline as we work to transform how cardiac care is delivered in the future.”